13,670 Shares in Tonix Pharmaceuticals Holding Corp. $TNXP Purchased by Rhumbline Advisers

Key Points

• Rhumbline Advisers has purchased 13,670 shares of Tonix Pharmaceuticals, representing a new stake valued at approximately $244,000, as reported in their latest SEC filing.
• Tonix Pharmaceuticals' stock recently saw a decline of 2.8%, with a current market price of $24.00, amidst a significant level of institutional ownership at 82.26%.
• The company reported a quarterly loss per share of ($3.86), missing analysts' expectations, and has a consensus target price of $70.00 according to recent analyst ratings.

Rhumbline Advisers acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,670 shares of the company's stock, valued at approximately $244,000. Rhumbline Advisers owned 0.19% of Tonix Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Royal Bank of Canada bought a new stake in Tonix Pharmaceuticals during the 1st quarter valued at $610,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Tonix Pharmaceuticals during the 1st quarter worth $405,000. IFP Advisors Inc purchased a new stake in shares of Tonix Pharmaceuticals during the 1st quarter worth $179,000. Two Sigma Investments LP bought a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $66,000. Finally, Jane Street Group LLC grew its stake in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after purchasing an additional 1,635,119 shares during the last quarter. Hedge funds and other institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Stock Down 2.8%

Tonix Pharmaceuticals stock opened at $24.00 on Friday. The stock has a 50-day moving average price of $37.04 and a 200 day moving average price of $30.43. The company has a market capitalization of $210.48 million, a price-to-earnings ratio of -0.61 and a beta of 1.86. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $6.76 and a 52 week high of $130.00.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative return on equity of 57.93% and a negative net margin of 828.22%.The business had revenue of $2.00 million for the quarter, compared to analysts' expectations of $2.60 million. Research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TNXP shares. Alliance Global Partners reaffirmed a "buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, June 3rd. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $70.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Want to see what other hedge funds are holding TNXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.